In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as EC Healthcare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:2138 - Analysts future estimates and past financials data (HKD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2025	4,803	128	N/A	897	1
9/30/2024	4,153	-12	632	793	N/A
6/30/2024	4,182	-15	580	741	N/A
3/31/2024	4,211	-19	528	689	N/A
12/31/2023	4,157	-11	422	709	N/A
9/30/2023	4,104	-4	317	729	N/A
6/30/2023	3,989	33	255	667	N/A
3/31/2023	3,875	70	193	605	N/A
12/31/2022	3,622	93	162	499	N/A
9/30/2022	3,369	117	132	392	N/A
6/30/2022	3,144	157	240	500	N/A
3/31/2022	2,920	198	348	608	N/A
12/31/2021	2,823	253	479	684	N/A
9/30/2021	2,727	309	610	760	N/A
6/30/2021	2,404	251	541	690	N/A
3/31/2021	2,080	193	472	621	N/A
12/31/2020	1,854	163	487	597	N/A
9/30/2020	1,627	133	503	573	N/A
6/30/2020	1,788	210	505	574	N/A
3/31/2020	1,949	287	507	576	N/A
12/31/2019	2,023	325	273	452	N/A
9/30/2019	2,098	364	40	327	N/A
6/30/2019	1,975	363	-5	283	N/A
3/31/2019	1,852	361	-49	238	N/A
12/31/2018	1,715	355	108	278	N/A
9/30/2018	1,578	348	265	317	N/A
6/30/2018	1,450	314	N/A	320	N/A
3/31/2018	1,322	279	N/A	324	N/A
12/31/2017	1,253	266	N/A	302	N/A
9/30/2017	1,183	253	N/A	280	N/A
6/30/2017	1,079	227	N/A	230	N/A
3/31/2017	975	201	N/A	180	N/A
12/31/2016	878	170	N/A	123	N/A
9/30/2016	780	139	N/A	66	N/A
6/30/2016	744	144	N/A	71	N/A
3/31/2016	708	149	N/A	76	N/A
12/31/2015	688	166	N/A	105	N/A
9/30/2015	668	183	N/A	134	N/A
6/30/2015	645	179	N/A	146	N/A
3/31/2015	621	174	N/A	159	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2138's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if 2138's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2138's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2138's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 2138's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 2138's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/27 07:29
End of Day Share Price	2025/05/27 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

EC Healthcare is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	China International Capital Corporation Limited
Zhuonan Xu	China International Capital Corporation Limited
null null	CMB International Securities Limited

EC Healthcare Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Ec Healthcare Provides Sales Expectations for Six Months Ended 30 September 2024

Price target increased by 35% to HK$2.84

EC Healthcare Provides Group Earnings Guidance for the Period from 1 April 2024 to 30 June 2024

Price target decreased by 15% to HK$5.22

Ec Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2023

Consensus EPS estimates fall by 31%

Recent updates

New major risk - Revenue and earnings growth

New minor risk - Market cap size

EC Healthcare's (HKG:2138) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Does EC Healthcare (HKG:2138) Have A Healthy Balance Sheet?

New major risk - Share price stability

New minor risk - Market cap size

Upcoming dividend of HK$0.01 per share

EC Healthcare (HKG:2138) Shares Fly 29% But Investors Aren't Buying For Growth

Dividend of HK$0.01 announced

First half 2025 earnings released: EPS: HK$0.012 (vs HK$0.006 in 1H 2024)

EC Healthcare Declares Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended 30 September 2024, Payable on 24 January 2025

New minor risk - Market cap size

EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends

EC Healthcare to Report First Half, 2025 Results on Nov 28, 2024

Ec Healthcare Provides Sales Expectations for Six Months Ended 30 September 2024

Price target increased by 35% to HK$2.84

Less than half of directors are independent

Little Excitement Around EC Healthcare's (HKG:2138) Revenues As Shares Take 31% Pounding

EC Healthcare Provides Group Earnings Guidance for the Period from 1 April 2024 to 30 June 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

EC Healthcare (HKG:2138) Might Be Having Difficulty Using Its Capital Effectively

Full year 2024 earnings: EPS and revenues miss analyst expectations

EC Healthcare, Annual General Meeting, Aug 23, 2024

EC Healthcare to Report Fiscal Year 2024 Results on Jun 27, 2024

An undisclosed buyer entered into an agreement to acquire additional 51% stake in Preeminent Medical Centre Limited from EC Healthcare (SEHK:2138) for HKD 80.2 million.

EC Healthcare (HKG:2138) Surges 25% Yet Its Low P/S Is No Reason For Excitement

When Should You Buy EC Healthcare (HKG:2138)?

Is EC Healthcare (HKG:2138) A Risky Investment?

New minor risk - Share price stability

Slammed 26% EC Healthcare (HKG:2138) Screens Well Here But There Might Be A Catch

EC Healthcare's (HKG:2138) Dividend Is Being Reduced To HK$0.005

EC Healthcare Announces the Resignation of Mr. Wong Chi Cheung as Executive Director and Chief Digital Officer of the Company with Effect from 31 December 2023

Price target decreased by 15% to HK$5.22

First half 2024 earnings released: EPS: HK$0.006 (vs HK$0.068 in 1H 2023)

Here's What's Concerning About EC Healthcare's (HKG:2138) Returns On Capital

EC Healthcare Declares an Interim Dividend for the Six Months Ended 30 September 2023, Payable on January 19, 2024

Ec Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2023

EC Healthcare to Report First Half, 2024 Results on Nov 30, 2023

EC Healthcare Announces Executive Changes

At HK$3.13, Is EC Healthcare (HKG:2138) Worth Looking At Closely?

Ec Healthcare Approves Dividend for the Year Ended 31 March 2023, Payment Date Is 18 September 2023

Upcoming dividend of HK$0.042 per share at 2.6% yield

EC Healthcare (HKG:2138) Is Paying Out A Dividend Of HK$0.042

Ec Healthcare Approves Final Dividend for the Year Ended 31 March 2023

Is EC Healthcare (HKG:2138) Using Too Much Debt?

New minor risk - Earnings quality

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EC Healthcare (HKG:2138) Has Announced A Dividend Of HK$0.042

Consensus EPS estimates fall by 31%

EC Healthcare (HKG:2138) Will Pay A Dividend Of HK$0.042

Price target decreased by 11% to HK$8.03

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EC Healthcare, Annual General Meeting, Aug 23, 2023

EC Healthcare Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023

Is There Now An Opportunity In EC Healthcare (HKG:2138)?

EC Healthcare to Report Fiscal Year 2023 Final Results on Jun 23, 2023

Be Wary Of EC Healthcare (HKG:2138) And Its Returns On Capital

Is EC Healthcare (HKG:2138) Potentially Undervalued?

EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends

Price target increased to HK$9.33

Price target increased to HK$8.04

Upcoming dividend of HK$0.058 per share

EC Healthcare (HKG:2138) Is Paying Out Less In Dividends Than Last Year

Investor sentiment improved over the past week

Consensus forecasts updated

First half 2023 earnings released

Price target decreased to HK$8.89

Less than half of directors are independent

Investor sentiment improved over the past week